PrenatalScreen® Standard
The PrenatalScreen® Standard test includes the analysis of a wide number of genes and the most common and clinically relevant diseases (740+ genes, 1000+ genetic conditions).
OncoNext™ Risk – Ovarian
OncoNext™ Risk Ovarian is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of uterus and ovary cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Colon
OncoNext™ Risk Colon is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of colorectal cancer or Familial Adenomatous Polyposis. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Prostate
OncoNext™ Risk Prostate is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Prostate cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Renal
OncoNext™ Risk Renal is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Kidney cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Pancreas
OncoNext™ Risk – Oncoscreening Complete
OncoNext ™ Risk OncoScreening Complete is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to hereditary cancers, including: Breast Cancer, Ovarian / Uterus Cancer, Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Prostate Cancer, Skin Cancer (Melanoma), Brain Cancer, Kidney Cancer and Pheochromocytoma / Paraganglioma. […]
